177 related articles for article (PubMed ID: 25261661)
1. Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer.
Zhang T; Zhang DM; Zhao D; Hou XM; Yang TN
J BUON; 2014; 19(3):742-8. PubMed ID: 25261661
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
3. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
Vassalou H; Stathopoulos E; Fiolitaki G; Koutsopoulos A; Voutsina A; Georgoulias V; Mavroudis D
Lung Cancer; 2013 Nov; 82(2):324-9. PubMed ID: 23993732
[TBL] [Abstract][Full Text] [Related]
4. Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Du G; Yang Y; Zhang Y; Sun T; Liu W; Wang Y; Li J; Zhang H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):893-904. PubMed ID: 23355038
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
Zhang YF; Chen ZW; Lu S
Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
[TBL] [Abstract][Full Text] [Related]
6. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection.
Sun BS; Li Y; Zhang ZF; You J; Wang CL
Ann Thorac Surg; 2013 Dec; 96(6):1943-51. PubMed ID: 24094519
[TBL] [Abstract][Full Text] [Related]
8. Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer?
Inal A; Kaplan MA; Kucukoner M; Urakcı Z; Kılınc F; Isıkdogan A
Rev Port Pneumol; 2014; 20(2):62-8. PubMed ID: 24210228
[TBL] [Abstract][Full Text] [Related]
9. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer.
Liu H; Zhang T; Li X; Huang J; Wu B; Huang X; Zhou Y; Zhu J; Hou J
Cancer Sci; 2008 Nov; 99(11):2185-92. PubMed ID: 18823373
[TBL] [Abstract][Full Text] [Related]
11. [Effect of pemetrexed plus platinum for chemotherapy-naive advanced non-small cell lung cancer].
Duan JC; Wu MN; Zhao J; An TT; Yang L; Bai H; Wang ZJ; Zhuo ML; Wang SH; Wang YY; Liu XH; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):97-101. PubMed ID: 22455964
[TBL] [Abstract][Full Text] [Related]
12. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
13. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.
Ng R; Loreto M; Lee R; Leighl NB
Lung Cancer; 2008 Aug; 61(2):262-5. PubMed ID: 18358559
[TBL] [Abstract][Full Text] [Related]
14. Platinum-based doublet chemotherapy plus bevacizumab without bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC).
Nørøxe DS; Wallerek S; Sørensen JB
Anticancer Res; 2013 Aug; 33(8):3275-8. PubMed ID: 23898091
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
[TBL] [Abstract][Full Text] [Related]
16. Non-platinum-based first-line followed by platinum-based second-line chemotherapy or the reverse sequence in patients with advanced non-small cell lung cancer: a retrospective analysis by the lung cancer group of the Hellenic Oncology Research Group.
Agelaki S; Hatzidaki D; Kotsakis A; Papakotoulas P; Polyzos A; Ziras N; Gioulbasanis I; Karampeazis A; Agelidou A; Tsiafaki X; Chandrinos V; Lerikou M; Georgoulias V
Oncology; 2010; 78(3-4):229-36. PubMed ID: 20523083
[TBL] [Abstract][Full Text] [Related]
17. ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.
Das M; Riess JW; Frankel P; Schwartz E; Bennis R; Hsieh HB; Liu X; Ly JC; Zhou L; Nieva JJ; Wakelee HA; Bruce RH
Lung Cancer; 2012 Aug; 77(2):421-6. PubMed ID: 22555222
[TBL] [Abstract][Full Text] [Related]
18. Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
Kotake M; Miura Y; Imai H; Mori K; Sakurai R; Kaira K; Tomizawa Y; Minato K; Saito R; Hisada T
Chemotherapy; 2017; 62(4):205-213. PubMed ID: 28380484
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
